| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
108,030,000 |
| Market
Cap: |
54.46(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4901 - $1.4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Selecta Biosciences is a clinical-stage biopharmaceutical company. Co.'s ImmTOR® platform encapsulates rapamycin, also known as sirolimus, a Food and Drug Administration approved immunomodulator, in biodegradable nanoparticles ImmTOR is designed to induce antigen-specific immune tolerance. By combining ImmTOR with antigens of interest, Co.'s immune tolerance platform restores self-tolerance to auto-antigens in autoimmune diseases, amplify the ability of biologics (including gene therapies) and mitigate the formation of anti-drug antibodies against biologic drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,222,516 |
1,223,316 |
1,223,316 |
1,403,316 |
| Total Buy Value |
$688,511 |
$689,063 |
$689,063 |
$877,582 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
12 |
13 |
13 |
15 |
| Total Shares Sold |
0 |
0 |
3,637 |
15,619 |
| Total Sell Value |
$0 |
$0 |
$3,855 |
$23,149 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
2 |
5 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kishimoto Takashi Kei |
Chief Scientific Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
164,149 |
|
- |
|
| Johnston Lloyd P. |
COO and SVP, R&D |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
57,734 |
|
- |
|
| Traber Peter G |
Chief Medical Officer |
• – – |
2020-12-14 |
4 |
B |
$3.24 |
$129,424 |
D/D |
40,000 |
40,000 |
2.74 |
26% |
|
| Brunn Carsten |
President and CEO |
• • – |
2020-12-02 |
4 |
S |
$3.35 |
$11,134 |
D/D |
(3,323) |
101,350 |
|
-17% |
|
| Brunn Carsten |
President and CEO |
• • – |
2020-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,938 |
104,673 |
|
- |
|
| Kishimoto Takashi Kei |
Chief Scientific Officer |
• – – |
2020-10-23 |
4 |
OE |
$2.77 |
$83,100 |
D/D |
30,000 |
126,149 |
|
- |
|
| Springer Timothy A |
Director |
– • • |
2020-10-23 |
4 |
B |
$2.71 |
$2,699,737 |
I/I |
994,488 |
14,480,948 |
2.25 |
34% |
|
| Springer Timothy A |
Director |
– • • |
2020-10-22 |
4 |
B |
$2.63 |
$4,656,699 |
I/I |
1,770,204 |
13,486,460 |
2.25 |
42% |
|
| Springer Timothy A |
Director |
– • • |
2020-10-21 |
4 |
B |
$2.50 |
$2,199,472 |
I/I |
880,000 |
11,716,256 |
2.25 |
55% |
|
| Springer Timothy A |
Director |
– • • |
2020-10-20 |
4 |
B |
$2.21 |
$2,013,193 |
I/I |
910,000 |
10,836,256 |
2.25 |
94% |
|
| Springer Timothy A |
Director |
– • • |
2020-10-19 |
4 |
B |
$2.36 |
$1,795,002 |
I/I |
759,500 |
9,926,256 |
2.25 |
93% |
|
| Springer Timothy A |
Director |
– • • |
2020-10-16 |
4 |
B |
$2.42 |
$528,034 |
I/I |
218,196 |
9,166,756 |
2.25 |
69% |
|
| Springer Timothy A |
Director |
– • • |
2020-10-09 |
4 |
B |
$2.00 |
$552,465 |
I/I |
276,703 |
8,948,560 |
2.25 |
129% |
|
| Springer Timothy A |
Director |
– • • |
2020-10-08 |
4 |
B |
$1.89 |
$1,000,836 |
I/I |
530,441 |
8,671,857 |
2.25 |
143% |
|
| Springer Timothy A |
Director |
– • • |
2020-10-07 |
4 |
B |
$1.65 |
$1,078,577 |
I/I |
654,953 |
8,141,416 |
2.25 |
180% |
|
| Springer Timothy A |
Director |
– • • |
2020-10-06 |
4 |
B |
$1.68 |
$3,365,800 |
I/I |
2,000,000 |
7,486,463 |
2.25 |
204% |
|
| Barabe Timothy C |
Director |
– • – |
2020-10-06 |
4 |
B |
$1.68 |
$83,985 |
D/D |
50,000 |
171,013 |
2.39 |
204% |
|
| Brunn Carsten |
President and CEO |
• • – |
2020-09-02 |
4 |
S |
$2.39 |
$8,035 |
D/D |
(3,364) |
93,735 |
|
-54% |
|
| Brunn Carsten |
President and CEO |
• • – |
2020-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,937 |
97,099 |
|
- |
|
| Barabe Timothy C |
Director |
– • – |
2020-06-24 |
4 |
OE |
$1.46 |
$47,946 |
D/D |
32,840 |
121,013 |
|
- |
|
| Brunn Carsten |
President and CEO |
• • – |
2020-06-02 |
4 |
S |
$3.86 |
$12,557 |
D/D |
(3,253) |
86,162 |
|
44% |
|
| Brunn Carsten |
President and CEO |
• • – |
2020-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,938 |
89,415 |
|
- |
|
| Barabe Timothy C |
Director |
– • – |
2020-03-17 |
4 |
B |
$2.00 |
$10,000 |
D/D |
5,000 |
88,173 |
2.39 |
27% |
|
| Brunn Carsten |
President and CEO |
• • – |
2020-03-03 |
4 |
S |
$3.86 |
$13,011 |
D/D |
(3,374) |
78,477 |
|
36% |
|
| Brunn Carsten |
President and CEO |
• • – |
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,937 |
81,851 |
|
- |
|
258 Records found
|
|
Page 6 of 11 |
|
|
